All In Biotech

Drug Trial Radar · NCT03622593

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 951 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

951

Actual

Start

Oct 9, 2018

Primary completion

Oct 19, 2020

Study completion May 31, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

Conditions

  • Diabetic Macular Edema

Interventions

  • AfliberceptDrug

    Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).

  • FaricimabDrug

    Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.

  • Sham ProcedureProcedure

    The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive PopulationsTime frame: From Baseline through Week 56

Locations

188 sites in 24 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona

  • Retinal Research Institute, LLC

    Phoenix, Arizona

  • Northwest Arkansas Retina Associates

    Springdale, Arkansas

  • California Retina Consultants

    Bakersfield, California

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • The Retina Partners

    Encino, California

  • Retina Consultants of Orange County

    Fullerton, California

  • Northern California Retina Vitreous Associates

    Mountain View, California

  • Retinal Consultants Med Group

    Sacramento, California

  • California Retina Consultants

    Santa Barbara, California

  • California Retina Consultants

    Santa Maria, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • University of Colorado

    Aurora, Colorado

  • Retina Consultants of Southern

    Colorado Springs, Colorado

  • Retina Group of New England

    Waterford, Connecticut

  • Retina Group of Florida

    Fort Lauderdale, Florida

  • National Ophthalmic Research Institute

    Fort Myers, Florida

  • Florida Eye Associates

    Melbourne, Florida

  • Bascom Palmer Eye Institute

    Palm Beach Gardens, Florida

  • Fort Lauderdale Eye Institute

    Plantation, Florida

  • Retina Vitreous Assoc of FL

    St. Petersburg, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Prairie Retina Center

    Springfield, Illinois

  • Retina Specialists

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Associated Retinal Consultants

    Grand Rapids, Michigan

  • Vitreo-Retinal Associates

    Grand Rapids, Michigan

  • Retina Consultants of Nevada

    Las Vegas, Nevada

  • Envision Ocular, LLC

    Bloomfield, New Jersey

  • Long Is. Vitreoretinal Consult

    Hauppauge, New York

  • New York University

    New York, New York

  • Ophthalmic Cons of Long Island

    Oceanside, New York

  • Retina Assoc of Western NY

    Rochester, New York

  • University of Rochester Flaum Eye Institute

    Rochester, New York

  • The Retina Consultants

    Slingerlands, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Mid Atlantic Retina - Wills Eye Hospital

    Philadelphia, Pennsylvania

  • Retina Consultants Of Carolina

    Greenville, South Carolina

  • Charleston Neuroscience Inst

    Ladson, South Carolina

Showing 40 of 188 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.